

In the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-23 (canceled)

24. (currently amended) A pharmaceutical composition, comprising:

(a) at least one polynucleotide, wherein the polynucleotide comprises a sequence of a binding site for a transcription factor and which is selected from the group consisting of GATTGCCTGACGTCAGAGAG (SEQ ID NO:8), GGAATGACGTTCCCTGTG (SEQ ID NO:9), AGCTATGACGTTCCAAGG (SEQ ID NO:10), GCTTGATGACTCAGCCGGAA (SEQ ID NO:11), TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12), TGCAGATTGCGCAATCTGCA (SEQ ID NO:13), AGCGGGGGCGAGCGGGGGCG (SEQ ID NO:14), GTCCATTTCCCGTAAATCTT (SEQ ID NO:16), TATGCATATTCCTGTAAGTG (SEQ ID NO:17), CTGATTTCCTCCGAAATGATG (SEQ ID NO:19), AGATTTCTAGGAATTCAATC (SEQ ID NO:20), GTATTTCCCAGAAAAGGAAC (SEQ ID NO:21), AAGCGAAAATGAAATTGACT (SEQ ID NO:22), and CAGGCATAACGGTTCCGTAG (SEQ ID NO:23); ~~and~~

(b) at least one antigen; and

~~(b)~~ (c) a pharmaceutically acceptable carrier and/or diluent.

25. (canceled)

26. (previously presented) The pharmaceutical composition according to claim 24 characterized in that the polynucleotide comprises at least one phosphorothioate linkage.

27. (currently amended) The pharmaceutical composition according to claim ~~25~~ 24, wherein the antigen is selected from the group consisting of peptides, polypeptides, proteins, polysaccharides, steroids, tumor cell antigens, and tumor cells.

28. (canceled)

29. (canceled)

Claims 30-39 (canceled)

40. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence GATTGCCTGACGTCAGAGAG (SEQ ID NO:8).

41. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence GGAATGACGTTCCCTGTG (SEQ ID NO:9).

42. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence AGCTATGACGTTCCAAGG (SEQ ID NO:10).

43. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence GCTTGATGACTCAGCCGGAA (SEQ ID NO:11).

44. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12).

45. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence TGCAGATTGCGCAATCTGCA (SEQ ID NO:13).

46. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence AGCGGGGGCGAGCGGGGGCG (SEQ ID NO:14).

47. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence GTCCATTTCCTGTAAGTG (SEQ ID NO:16).
48. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence TATGCATATTCCTGTAAGTG (SEQ ID NO:17).
49. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence CTGATTTCCTGTAAGTG (SEQ ID NO:19).
50. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence AGATTTCCTGTAAGTG (SEQ ID NO:20).
51. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence GTATTTCCTGTAAGTG (SEQ ID NO:21).
52. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence AAGCGAAAATGAAATTGACT (SEQ ID NO:22).
53. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide comprises a sequence CAGGCATAACGGTTCCTGAG (SEQ ID NO:23).
54. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence GATTGCCTGACGTCAGAGAG (SEQ ID NO:8).
55. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence GGAATGACGTTCCCTGTG (SEQ ID NO:9).

56. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence AGCTATGACGTTCCAAGG (SEQ ID NO:10).
57. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence GCTTGATGACTCAGCCGGAA (SEQ ID NO:11).
58. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12).
59. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence TGCAGATTGCGCAATCTGCA (SEQ ID NO:13).
60. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence AGCGGGGGCGAGCGGGGGCG (SEQ ID NO:14).
61. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence GTCCATTCCCGTAAATCTT (SEQ ID NO:16).
62. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence TATGCATATTCCTGTAAGTG (SEQ ID NO:17).
63. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence CTGATTTCCCCGAAATGATG (SEQ ID NO:19).

64. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence AGATTTCTAGGAATTCAATC (SEQ ID NO:20).
65. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence GTATTTCCCAGAAAAGGAAC (SEQ ID NO:21).
66. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence AAGCGAAAATGAAATTGACT (SEQ ID NO:22).
67. (new) The pharmaceutical composition according to claim 24, wherein the polynucleotide is an oligonucleotide consisting of a sequence CAGGCATAACGGTTCCGTAG (SEQ ID NO:23).
68. (new) The pharmaceutical composition according to any one of claims 40-53, wherein the polynucleotide comprises at least one phosphorothioate linkage.
69. (new) The pharmaceutical composition according to any one of claims 54-67, wherein the oligonucleotide comprises at least one phosphorothioate linkage.
70. (new) The pharmaceutical composition according to any one of claims 40-67, wherein the antigen is selected from the group consisting of peptides, polypeptides, proteins, polysaccharides, steroids, tumor cell antigens, and tumor cells.